Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

20.11.24	Sanofi: Information concerning the total number of voting rights and shares - October 2024 (GlobeNewswire)
15.11.24	Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria (RTTNews)
15.11.24	Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (GlobeNewswire)
14.11.24	Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
06.11.24	Regeneron: EC Approves Dupixent For Young Children With EoE (RTTNews)
06.11.24	Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis (GlobeNewswire)
29.10.24	Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall (RTTNews)
25.10.24	Sanofi Q3 Profit Rises - Quick Facts (RTTNews)
25.10.24	Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance (GlobeNewswire)
24.10.24	Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI (GlobeNewswire)
21.10.24	Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R (RTTNews)
21.10.24	Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare (GlobeNewswire)
17.10.24	PAI Partners Raises Offer For Sanofi's Consumer Health Biz Opella: Reports (RTTNews)
17.10.24	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
17.10.24	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
16.10.24	FDA Updates Sanofi's FLUBLOK Vaccine Label With New Safety Data For Pregnant Individuals (RTTNews)
15.10.24	Sanofi: Information concerning the total number of voting rights and shares - September 2024 (GlobeNewswire)
11.10.24	Press Release: Sanofi in discussions to sell a controlling stake in Opella (GlobeNewswire)
09.10.24	Sanofi : Beyfortus Data Reinforce Effectiveness Against RSV Disease & Hospitalization In Infants (RTTNews)
09.10.24	Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants (GlobeNewswire)
27.09.24	Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment (RTTNews)
27.09.24	Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
27.09.24	Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease (RTTNews)
27.09.24	Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
26.09.24	Press Release: Availability of the Q3 2024 Aide mémoire (GlobeNewswire)
21.09.24	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans (GlobeNewswire)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (EN, Sanofi-Aventis)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (GlobeNewswire)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (GlobeNewswire)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (EN, Sanofi-Aventis)
16.09.24	Sanofi: Information concerning the total number of voting rights and shares - August 2024 (GlobeNewswire)
16.09.24	Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts (RTTNews)
12.09.24	Sanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare Cancers (RTTNews)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (GlobeNewswire)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (EN, Sanofi-Aventis)
11.09.24	Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints (RTTNews)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (GlobeNewswire)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (GlobeNewswire)
10.09.24	Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies (EN, Sanofi-Aventis)
02.09.24	Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS (RTTNews)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (EN, Sanofi-Aventis)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (GlobeNewswire)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
26.08.24	Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases (EN, Sanofi-Aventis)
09.08.24	Sanofi: Information concerning the total number of voting rights and shares - July 2024 (GlobeNewswire)
08.08.24	Sanofi : Sarclisa Induction Treatment Improves PFS In Transplant-Eligible Myeloma Patients (RTTNews)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (EN, Sanofi-Aventis)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	548.60	3.31 %	K V
Logitech Intl	70.30	2.63 %	K V
Givaudan	3’930.00	1.73 %	K V
Swiss Re	127.60	1.31 %	K V
ABB	49.53	0.98 %	K V
Kuehne+Nagel Int	208.00	-0.10 %	K V
Sika	229.30	-0.22 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	76.00	-0.68 %	K V
CieFinRichemont	117.60	-0.84 %	K V

mehr

16:52		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:17		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
16:02		S&P 500-Titel Moderna-Aktie: So viel hätte eine Investition in Moderna von vor einem Jahr gekostet
15:58		Schwache Performance in Zürich: SPI notiert nachmittags im Minus
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer
15:58		Minuszeichen in Frankfurt: SDAX am Nachmittag leichter